CRISPR Therapeutics to Participate in Upcoming Investor Conferences
May 26, 2020 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
May 15, 2020 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
May 14, 2020 09:02 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new...
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
May 11, 2020 09:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 11, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the...
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
May 07, 2020 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
April 28, 2020 16:45 ET
|
CRISPR Therapeutics AG
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+ malignancies- -Began treating...
CRISPR Therapeutics Proposes Changes to the Board of Directors
February 26, 2020 16:05 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
February 12, 2020 16:05 ET
|
CRISPR Therapeutics AG
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+ malignancies- -Enrollment has...
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
January 06, 2020 16:05 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics to Present at Upcoming Investor Conferences
November 27, 2019 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...